Resources

January 25, 2017 | Podcasts

iBrief: What Changes Are Coming for the 340B Drug Pricing Program and How Will They Affect Pharmaceutical Manufacturers?

brief_logo1HRSA Releases Final Rule for 340B Drug Pricing Program

On Jan. 5, the Health Resources and Services Administration (HRSA) issued a final rule regarding the 340B Drug Pricing Program. This federally managed program allows certain types of hospitals to receive special pricing on outpatient drugs from drug manufacturers.

Under the final rule, pharmaceutical companies are subject to civil monetary penalties (CMPs) that are essentially fines.

Although manufacturers have always been required to not overcharge covered entities in the 340B program, the final rule penalizes companies that do overcharge. Under the final rule, a company could be fined up to $5,000 for each time it “knowingly and intentionally” overcharges a hospital for a drug.

Under the final rule, manufacturers also are required to offer refunds for overcharges on new drugs.

In our newest iBrief podcast, we discuss some of the basics of the 340B Drug Pricing Program and the changes coming for pharmaceutical manufacturers.

Listen to the Free Podcast HERE. iBrief will deliver up-to-date, relevant content on changes occurring in the healthcare landscape.

Read our blog HERE about our 340b eModule now available 

Subscribe to our blog to stay up-to-date on newly released podcasts, eModules, and updates.

Subscribe to Get More Great Posts